Personalis Q1 Revenue $15.5M, Exceeds Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy PSNL?
Reports Q1 revenue $15.5M, consensus $14.5M. "Our accomplishments in the first quarter demonstrated that our 'Win-in-MRD' strategy is working to establish NeXT Personal as the new standard for how cancer is detected and monitored," said Chris Hall, Chief Executive Officer of Personalis. "Delivering 26% sequential and 258% year-over-year clinical volume growth-especially during what is traditionally the industry's toughest seasonal quarter reflects the strong market demand for our ultrasensitive NeXT Personal test. With new Medicare coverage for lung cancer joining our existing breast cancer win, Personalis now has a reimbursement success in two of the largest oncology indications. We are transforming our ultrasensitive MRD technology from a clinical leader into a potential commercial powerhouse and we remain firmly on track to grow our clinical revenue five-fold this year."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PSNL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PSNL
Wall Street analysts forecast PSNL stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 5.980
Low
10.00
Averages
11.17
High
12.00
Current: 5.980
Low
10.00
Averages
11.17
High
12.00
About PSNL
Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Personalis Q1 2026 Earnings Call Insights
- Clinical Test Acceleration: In Q1 2026, Personalis delivered over 7,800 clinical tests, significantly up from 6,183 in the previous quarter, indicating a growing acceptance of NeXT Personal and enhancing the company's competitive position in the MRD market.
- Stable Revenue Outlook: The company expects total revenue for 2026 to be between $78 million and $80 million, despite reporting $15.5 million in Q1, a 25% year-over-year decline, which management emphasizes is a necessary transition towards higher-growth clinical and biopharma revenues.
- Margin Pressure: The gross margin for Q1 was only 1.8%, primarily due to unreimbursed test costs diluting margins by over 2,000 basis points, with management anticipating margin improvement in the coming quarters as clinical volumes scale up, reflecting short-term financial challenges.
- Market Expansion and Partnerships: The collaboration with Tempus resulted in over 1,000 ordering physicians in Q1, demonstrating progress in commercialization, and the company plans to continue expanding its market footprint to support its long-term growth strategy.
See More
Personalis (PSNL) Q1 2026 Earnings Transcript
See More
Personalis Showcases NeXT Personal's Role in Colorectal Cancer Treatment
- Clinical Data Presentation: At the American Association for Cancer Research Annual Meeting, Personalis showcased the application of NeXT Personal in monitoring neoadjuvant therapy for colorectal cancer, supported by real-world data from 10,000 patients, confirming its industry-leading sensitivity for treatment response and early recurrence monitoring.
- NEOPRISM-CRC Trial Highlights: The trial revealed that 100% of 'super molecular responders' cleared ctDNA by the second treatment cycle and achieved pathological complete response (pCR), while 'poor molecular responders' did not reach pCR, indicating a critical opportunity for clinicians to adjust treatment strategies prior to surgery.
- Ultrasensitive Performance Validation: Analysis of nearly 25,000 plasma samples demonstrated NeXT Personal's median limit of detection at 1.92 PPM, with 39% of positive minimal residual disease (MRD) detections occurring below 100 PPM, showcasing its robust performance across various cancer types and capturing low-concentration changes that traditional assays might miss.
- New Feature Launch: Personalis introduced the Real-Time Variant Tracker™, allowing simultaneous MRD monitoring and tracking of specific resistance mutations, achieving over 99.9% specificity, thus providing clinicians with a new tool to track the emergence of treatment resistance in MRD-positive patients.
See More
Personalis Showcases NeXT Personal's Application in Colorectal Cancer
- Innovative Testing Method: Personalis will debut the Real-Time Variant Tracker for NeXT Personal at the 2026 AACR Annual Meeting, aiming to enhance colorectal cancer management by monitoring therapy resistance mutations, marking a first in tumor-informed clinical MRD testing.
- Data Presentation Timing: The company will present its findings on April 20, 2026, during an oral session, focusing on ultrasensitive ctDNA monitoring in high-risk stage II-III dMMR/MSI colorectal cancer patients, highlighting its significance in predicting and tracking immunotherapy responses.
- Clinical Validation Results: On the same day, Personalis will share analytical validation and real-world data for the Real-Time Variant Tracker in a poster presentation, showcasing its capability to detect resistance and other clinical mutations during MRD testing, further solidifying its market position.
- Impact on Patient Management: Dr. Richard Chen emphasized that NeXT Personal's ultrasensitive ctDNA detection can provide critical patient management insights upon cancer recurrence, underscoring the company's strong commitment to innovation in cancer management.
See More
ARK Genomic Revolution ETF Underperforms
- ETF Performance: The ARK Genomic Revolution ETF is down approximately 5.7% in Friday afternoon trading, indicating a weak performance that could undermine investor confidence and lead to capital outflows.
- Stock Underperformance: Among the ETF's weakest components are Personalis, which fell about 12.2%, and Generate Biomedicines, down about 11.2%, suggesting increasing challenges in the biotech sector that may heighten investor concerns.
- Market Reaction: The negative performance of the ARK Genomic Revolution ETF has elicited strong reactions from investors, potentially prompting a reevaluation of valuations for related biotech companies, which could impact their future financing and growth plans.
- Industry Outlook: As market confidence in the biotech sector wanes, the performance of the ARK Genomic Revolution ETF may drive investors to reconsider their diversification strategies to mitigate risks and seek more stable returns.
See More
Personalis Publishes PREDICT-DNA Study Results
- Significant Findings: The PREDICT-DNA study published in the Journal of Clinical Oncology demonstrates that NeXT Personal's ultrasensitive ctDNA testing outperforms current standard methods in predicting outcomes for patients undergoing neoadjuvant therapy, involving 227 patients with Triple-Negative and HER2+ breast cancer.
- Strong Prognostic Power: The study reveals that patients with detectable ctDNA post-NAT have a 4 to 9 times higher likelihood of relapse, with ctDNA status identified as the most significant independent prognostic signal in multivariate analyses, surpassing traditional metrics like nodal status and tumor grade.
- Low-Risk Identification: Findings indicate that ctDNA-negative patients post-NAT exhibit excellent outcomes regardless of pCR status, underscoring NeXT Personal's potential for early clinical intervention.
- Clinical Application Prospects: The results support NeXT Personal's ultrasensitive detection capabilities, which may drive reimbursement expansion in neoadjuvant monitoring, aiding patients in understanding their treatment responses and informing subsequent therapy decisions.
See More
Personalis Q1 2026 Earnings Call Insights
- Clinical Test Acceleration: In Q1 2026, Personalis delivered over 7,800 clinical tests, significantly up from 6,183 in the previous quarter, indicating a growing acceptance of NeXT Personal and enhancing the company's competitive position in the MRD market.
- Stable Revenue Outlook: The company expects total revenue for 2026 to be between $78 million and $80 million, despite reporting $15.5 million in Q1, a 25% year-over-year decline, which management emphasizes is a necessary transition towards higher-growth clinical and biopharma revenues.
- Margin Pressure: The gross margin for Q1 was only 1.8%, primarily due to unreimbursed test costs diluting margins by over 2,000 basis points, with management anticipating margin improvement in the coming quarters as clinical volumes scale up, reflecting short-term financial challenges.
- Market Expansion and Partnerships: The collaboration with Tempus resulted in over 1,000 ordering physicians in Q1, demonstrating progress in commercialization, and the company plans to continue expanding its market footprint to support its long-term growth strategy.
See More
Personalis (PSNL) Q1 2026 Earnings Transcript
See More
Personalis Showcases NeXT Personal's Role in Colorectal Cancer Treatment
- Clinical Data Presentation: At the American Association for Cancer Research Annual Meeting, Personalis showcased the application of NeXT Personal in monitoring neoadjuvant therapy for colorectal cancer, supported by real-world data from 10,000 patients, confirming its industry-leading sensitivity for treatment response and early recurrence monitoring.
- NEOPRISM-CRC Trial Highlights: The trial revealed that 100% of 'super molecular responders' cleared ctDNA by the second treatment cycle and achieved pathological complete response (pCR), while 'poor molecular responders' did not reach pCR, indicating a critical opportunity for clinicians to adjust treatment strategies prior to surgery.
- Ultrasensitive Performance Validation: Analysis of nearly 25,000 plasma samples demonstrated NeXT Personal's median limit of detection at 1.92 PPM, with 39% of positive minimal residual disease (MRD) detections occurring below 100 PPM, showcasing its robust performance across various cancer types and capturing low-concentration changes that traditional assays might miss.
- New Feature Launch: Personalis introduced the Real-Time Variant Tracker™, allowing simultaneous MRD monitoring and tracking of specific resistance mutations, achieving over 99.9% specificity, thus providing clinicians with a new tool to track the emergence of treatment resistance in MRD-positive patients.
See More
Personalis Showcases NeXT Personal's Application in Colorectal Cancer
- Innovative Testing Method: Personalis will debut the Real-Time Variant Tracker for NeXT Personal at the 2026 AACR Annual Meeting, aiming to enhance colorectal cancer management by monitoring therapy resistance mutations, marking a first in tumor-informed clinical MRD testing.
- Data Presentation Timing: The company will present its findings on April 20, 2026, during an oral session, focusing on ultrasensitive ctDNA monitoring in high-risk stage II-III dMMR/MSI colorectal cancer patients, highlighting its significance in predicting and tracking immunotherapy responses.
- Clinical Validation Results: On the same day, Personalis will share analytical validation and real-world data for the Real-Time Variant Tracker in a poster presentation, showcasing its capability to detect resistance and other clinical mutations during MRD testing, further solidifying its market position.
- Impact on Patient Management: Dr. Richard Chen emphasized that NeXT Personal's ultrasensitive ctDNA detection can provide critical patient management insights upon cancer recurrence, underscoring the company's strong commitment to innovation in cancer management.
See More
ARK Genomic Revolution ETF Underperforms
- ETF Performance: The ARK Genomic Revolution ETF is down approximately 5.7% in Friday afternoon trading, indicating a weak performance that could undermine investor confidence and lead to capital outflows.
- Stock Underperformance: Among the ETF's weakest components are Personalis, which fell about 12.2%, and Generate Biomedicines, down about 11.2%, suggesting increasing challenges in the biotech sector that may heighten investor concerns.
- Market Reaction: The negative performance of the ARK Genomic Revolution ETF has elicited strong reactions from investors, potentially prompting a reevaluation of valuations for related biotech companies, which could impact their future financing and growth plans.
- Industry Outlook: As market confidence in the biotech sector wanes, the performance of the ARK Genomic Revolution ETF may drive investors to reconsider their diversification strategies to mitigate risks and seek more stable returns.
See More
Personalis Publishes PREDICT-DNA Study Results
- Significant Findings: The PREDICT-DNA study published in the Journal of Clinical Oncology demonstrates that NeXT Personal's ultrasensitive ctDNA testing outperforms current standard methods in predicting outcomes for patients undergoing neoadjuvant therapy, involving 227 patients with Triple-Negative and HER2+ breast cancer.
- Strong Prognostic Power: The study reveals that patients with detectable ctDNA post-NAT have a 4 to 9 times higher likelihood of relapse, with ctDNA status identified as the most significant independent prognostic signal in multivariate analyses, surpassing traditional metrics like nodal status and tumor grade.
- Low-Risk Identification: Findings indicate that ctDNA-negative patients post-NAT exhibit excellent outcomes regardless of pCR status, underscoring NeXT Personal's potential for early clinical intervention.
- Clinical Application Prospects: The results support NeXT Personal's ultrasensitive detection capabilities, which may drive reimbursement expansion in neoadjuvant monitoring, aiding patients in understanding their treatment responses and informing subsequent therapy decisions.
See More
